Vertex spends its cystic fibrosis profits on four new businesses

The technology

Vertex makes small molecules that fix the faulty CFTR protein in cystic fibrosis, and that franchise pays for everything else. In the second quarter, cystic fibrosis drugs brought in $3.21 billion of $3.33 billion in revenue. The company is moving patients from Trikafta to Alyftrek, which made $573.6 million in the quarter. In October it showed interim data in children aged 2 to 5 in which 37.5% of a 48-child substudy stopped pancreatic enzyme pills.

Outside cystic fibrosis, Vertex has spread its bets across very different tools. Casgevy is a CRISPR-edited cell therapy, now approved down to age 2. Journavx is a non-opioid pain pill that sells in the tens of millions per quarter. Povetacicept is an injected protein that blocks BAFF and APRIL in IgA nephropathy. Inaxaplin is a pill aimed at a genetic kidney disease. The Crinetics purchase adds the oral acromegaly drug Palsonify and the phase 3 adrenal drug atumelnant.

The odds

Povetacicept is the nearest event. It has a BLA under review with a November 30 decision date and large interim effects in a 605-patient phase 3 trial. The BIO and Informa base rates put the odds of approval after a filing at 90.6% across all diseases. That number does not account for the drug's own data, which look strong on proteinuria.

Inaxaplin is in phase 2/3. The base rate for moving from phase 3 to a filing is 57.8%. The AMPLIFIED data were encouraging in milder disease and weaker in patients with diabetes, and the trial that matters, AMPLITUDE, will be judged at interim on proteinuria and finally on two-year eGFR slope.

Atumelnant in classic CAH is a rare disease program in phase 3, where the base rate for reaching a filing is 60.4%. Zimislecel for type 1 diabetes is the riskiest of the large bets. Dosing was paused while Vertex ran a manufacturing analysis and resumed in the first quarter, with new timelines promised later in 2026.

The money

Vertex is very profitable. Second-quarter GAAP net income was $1.10 billion, and cash and investments were $13.6 billion on June 30. Full-year revenue guidance is $13.1 billion to $13.2 billion. The Crinetics deal cost about $8.8 billion net of cash and was paid with cash and debt, so the year-end balance sheet will look different. Vertex has said the deal adds to non-GAAP operating income only in 2029.

The risks

The first risk is concentration. About 96% of second-quarter revenue came from one disease, and the newer products are small. Casgevy and Journavx made about $126 million together last quarter.

The second is price discipline. Merger filings show Vertex raised its Crinetics bid several times while other suitors dropped out, and analysts at RBC and Stifel questioned the price.

The third is execution across new specialties. Vertex is building sales teams for kidney doctors, pain prescribers and now endocrinologists at the same time, and it ended the VX-522 cystic fibrosis program early for tolerability problems.

Our read

Vertex has the cash and the cystic fibrosis profits to keep buying and building. The next twelve months test whether that spending turns into a second leg. Povetacicept is the clearest near-term test: a filed drug with large effect sizes in a market that already has several competitors. Inaxaplin's interim AMPLITUDE data in early 2027 and Palsonify's early sales will tell investors whether the kidney and endocrine pillars can grow fast enough to matter against a $13 billion cystic fibrosis base. Zimislecel remains the long-dated wild card. The company reports third-quarter results on November 2.